{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:03Z","timestamp":1793933703596,"version":"4.8.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"The Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:23:42Z","timestamp":1788092622000},"page":"1402-1412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy"],"prefix":"10.1016","volume":"88","author":[{"given":"Yasuhiro","family":"Hamatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1748-4340","authenticated-orcid":false,"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitasha","family":"Sarswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joban","family":"Vaishnav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Kosheleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.07.022_bib1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.07.022_bib2","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.07.022_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.07.022_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","article-title":"Changing treatment landscape in transthyretin cardiac amyloidosis","volume":"18","author":"Fontana","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.07.022_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2026.07.022_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.07.022_bib8","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B Trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib10","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","article-title":"Impact of vutrisiran on functional capacity and quality of life in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Sheikh","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.jacc.2026.07.022_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.07.022_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.07.022_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jacc.2025.04.055","article-title":"Impact of vutrisiran on cardiac biomarkers in patients with transthyretin amyloidosis with cardiomyopathy from HELIOS-B","volume":"86","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.07.022_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacc.2026.07.022_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2025.09.1512","article-title":"Timing of mortality benefit in outcomes trials in transthyretin amyloidosis","volume":"87","author":"Claggett","year":"2026","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726072086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726072086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:31:22Z","timestamp":1790087482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726072086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726072086"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.022","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}